CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial

CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial

Abstract Background Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP)/CHOP-like chemotherapy is widely used in peripheral T cell lymphoma (PTCL). Here we conducted a phase 2, multicenter, randomized, controlled trial, comparing the efficacy and safety of CEOP/IVE/GDP alternating re...

Full description

Bibliographic Details
Main Authors: Ming-Ci Cai, Shu Cheng, Xin Wang, Jian-Da Hu, Yong-Ping Song, Yao-Hui Huang, Zi-Xun Yan, Yu-Jie Jiang, Xiao-Sheng Fang, Xiao-Yun Zheng, Li-Hua Dong, Meng-Meng Ji, Li Wang, Peng-Peng Xu, Wei-Li Zhao
Format: Article
Language:English
Published: BMC 2020-04-01
Series:Genome Medicine
Subjects:
Peripheral T cell lymphoma
Alternating regimen
CHOP
Overall response rate
Prognosis
Prognostic biomarker
Online Access:http://link.springer.com/article/10.1186/s13073-020-00739-0

Internet

http://link.springer.com/article/10.1186/s13073-020-00739-0

Similar Items